{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:56:58Z","timestamp":1762865818561,"version":"build-2065373602"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.clml.2011.01.002","type":"journal-article","created":{"date-parts":[[2011,5,24]],"date-time":"2011-05-24T04:26:38Z","timestamp":1306211198000},"page":"S25-S27","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"S1","title":["Prognostic Factors and Models in Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis"],"prefix":"10.1016","volume":"11","author":[{"given":"Francesco","family":"Passamonti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2011.01.002_bib1","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2007-04-083501","article-title":"Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel","volume":"110","author":"Tefferi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.01.002_bib2","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.amjmed.2004.06.032","article-title":"Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia","volume":"117","author":"Passamonti","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.clml.2011.01.002_bib3","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1182\/blood-2005-09-3826","article-title":"Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders","volume":"107","author":"Passamonti","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.01.002_bib4","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.01.002_bib5","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1182\/blood-2009-07-235119","article-title":"Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms","volume":"115","author":"Thoennissen","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.01.002_bib6","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1600-0609.2008.01038.x","article-title":"20+ yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosis","volume":"80","author":"Tefferi","year":"2008","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2011.01.002_bib7","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.01.002_bib8","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/leu.2008.72","article-title":"Life expectancy and prognostic factors in the classic BCR\/ABL-negative myeloproliferative disorders","volume":"22","author":"Cervantes","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2011.01.002_bib9","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood-2006-09-046342","article-title":"Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status","volume":"109","author":"Carobbio","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.01.002_bib10","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1200\/JCO.2007.15.3569","article-title":"Leukocytosis and risk stratification assessment in essential thrombocythemia","volume":"26","author":"Carobbio","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.01.002_bib11","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1182\/blood-2008-04-153783","article-title":"Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia","volume":"112","author":"Carobbio","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.01.002_bib12","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2006-08-042515","article-title":"Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera","volume":"109","author":"Landolfi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.01.002_bib13","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4065\/81.2.159","article-title":"Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors","volume":"81","author":"Wolanskyj","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2011.01.002_bib14","doi-asserted-by":"crossref","first-page":"5740","DOI":"10.1002\/cncr.24664","article-title":"Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera","volume":"115","author":"Gangat","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2011.01.002_bib15","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.3324\/haematol.13346","article-title":"Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients","volume":"93","author":"Passamonti","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2011.01.002_bib16","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/ajh.21360","article-title":"Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy","volume":"84","author":"Palandri","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2011.01.002_bib17","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1111\/j.1538-7836.2009.03531.x","article-title":"Increase in leukocyte count over time predicts thrombosis in patients with low-risk essential thrombocythemia","volume":"7","author":"Passamonti","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.clml.2011.01.002_bib18","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1182\/blood.V96.13.4261","article-title":"Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera","volume":"96","author":"Falanga","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.01.002_bib19","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1365-2141.2007.06674.x","article-title":"Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation","volume":"138","author":"Gangat","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2011.01.002_bib20","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1182\/blood-2007-01-066985","article-title":"The interaction between leukocytosis and other risk factors for thrombosis in essential thrombocythemia","volume":"109","author":"Tefferi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.01.002_bib21","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/leu.2010.5","article-title":"Leukocytosis is associated with poor survival but not with increased risk of thrombosis in essential thrombocythemia: a population-based study of 311 patients","volume":"24","author":"Girodon","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2011.01.002_bib22","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.leukres.2008.06.006","article-title":"Is JAK2 V617F mutation more than a diagnostic index?","volume":"33","author":"Dahabreh","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2011.01.002_bib23","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.thromres.2009.02.004","article-title":"Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review","volume":"124","author":"Lussana","year":"2009","journal-title":"Thromb Res"},{"key":"10.1016\/j.clml.2011.01.002_bib24","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","article-title":"Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia","volume":"110","author":"Vannucchi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.01.002_bib25","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/leu.2010.148","article-title":"A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications","volume":"24","author":"Passamonti","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2011.01.002_bib26","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2009-04-215848","article-title":"Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease","volume":"115","author":"Akada","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.01.002_bib27","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1182\/blood-2008-01-135897","article-title":"Characteristics and clinical correlates of MPL 515W>L\/K mutation in essential thrombocythemia","volume":"112","author":"Vannucchi","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.01.002_bib28","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood-2008-01-131664","article-title":"MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort","volume":"112","author":"Beer","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.01.002_bib29","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/leu.2009.47","article-title":"TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis","volume":"23","author":"Tefferi","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2011.01.002_bib30","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1200\/JCO.2008.20.3174","article-title":"Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy","volume":"27","author":"Campbell","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.01.002_bib31","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.01.002_bib32","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1182\/blood-2010-06-293415","article-title":"Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis","volume":"116","author":"Passamonti","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.01.002_bib33","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood.V88.3.1013.1013","article-title":"Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system","volume":"88","author":"Dupriez","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.01.002_bib34","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1046\/j.1365-2141.1997.1722990.x","article-title":"Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases","volume":"98","author":"Reilly","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2011.01.002_bib35","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1182\/blood-2009-12-255943","article-title":"Identification during the follow-up of time-dependent prognostic factors for the competing risks of death and blast phase in primary myelofibrosis: a study of 172 patients","volume":"115","author":"Morel","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.01.002_bib36","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood-2009-08-240135","article-title":"International Prognostic Scoring System: independent cytogenetic risk categorization in primary myelofibrosis","volume":"115","author":"Hussein","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.01.002_bib37","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1182\/blood-2008-09-178541","article-title":"The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course","volume":"113","author":"Tam","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.01.002_bib38","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1182\/blood-2009-12-258988","article-title":"Validation of cytogenetic-based risk stratification in primary myelofibrosis","volume":"115","author":"Rumi","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.01.002_bib39","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1182\/blood-2007-07-099184","article-title":"JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis","volume":"110","author":"Barosi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.01.002_bib40","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/sj.leu.2405097","article-title":"Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2011.01.002_bib41","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1182\/blood-2009-04-216044","article-title":"Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele","volume":"114","author":"Guglielmelli","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.01.002_bib42","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3324\/haematol.13721","article-title":"JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis","volume":"94","author":"Guglielmelli","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2011.01.002_bib43","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1182\/blood-2009-12-260588","article-title":"Impact of JAK2V617F-mutation status, allele burden and clearance after allogeneic stem cell transplantation for myelofibrosis","volume":"116","author":"Alchalby","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.01.002_bib44","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/ajh.21574","article-title":"Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis: prognostic relevance is independent of IPSS or karyotype","volume":"85","author":"Tefferi","year":"2010","journal-title":"Am J Hematoly"},{"key":"10.1016\/j.clml.2011.01.002_bib45","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/j.1365-2141.2010.08275.x","article-title":"Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence","volume":"150","author":"Passamonti","year":"2010","journal-title":"Br J Haematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011000309?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011000309?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:22:19Z","timestamp":1761870139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265011000309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":45,"alternative-id":["S2152265011000309"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2011.01.002","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2011,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic Factors and Models in Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2011.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}